Aluminum Oxide Causticum Claviceps Purpurea Sclero
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aluminum Oxide Causticum Claviceps Purpurea Sclero
- Aluminum Oxide / Causticum / Gelsemium Compound: No Repurposing Prediction Available
Aluminum Oxide / Causticum / Gelsemium Compound: No Repurposing Prediction Available
One-Sentence Summary
This compound is a multi-ingredient mixture of primarily homeopathic substances (Aluminum Oxide, Causticum, Claviceps Purpurea Sclerotium, Gelsemium Sempervirens, Lead, Moschus Moschiferus, Zinc) with no current regulatory approval in Taiwan. The TxGNN model was unable to generate any repurposing prediction for this compound due to insufficient mapping data. No supporting clinical trials or publications could be retrieved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None identified |
| Predicted New Indication | None (no prediction generated) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction not available |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
No repurposing prediction was generated by TxGNN for this compound. The seven listed components are characteristic of homeopathic preparations:
- Causticum, Gelsemium Sempervirens Root, Claviceps Purpurea Sclerotium, and Moschus Moschiferus Musk Sac Resin are classic single homeopathic remedies (simplex).
- Aluminum Oxide, Lead, and Zinc serve as inorganic homeopathic potentiates.
Currently, detailed mechanism of action data is not available. Based on known information, this compound is a homeopathic multi-ingredient formula. Since none of the individual components could be mapped to a DrugBank node as a unified entity, the TxGNN knowledge graph has no drug node from which to compute disease associations. Without a valid drug anchor in the graph, the model cannot generate repurposing candidates.
To enable a meaningful TxGNN analysis, each active ingredient would need to be evaluated separately using its individual DrugBank ID.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline could not generate any repurposing candidates because this compound lacks a unified DrugBank ID mapping and has no approved indication in any recognized regulatory database, making knowledge graph traversal impossible.
To proceed, the following is needed:
- Confirm whether this compound corresponds to a single registered product or is a custom homeopathic formula, and obtain the relevant product labeling
- Map each active ingredient individually to its DrugBank ID (e.g., Gelsemium Sempervirens → DB12452, Zinc → DB01593) and re-run TxGNN per ingredient
- Retrieve original approved indications from TFDA or international homeopathic pharmacopeias (e.g., HPUS, HAB)
- Collect mechanism of action data for any conventionally pharmacologically active components (e.g., ergot alkaloids from Claviceps purpurea)
- Assess lead (Plumbum metallicum) safety profile given known heavy-metal toxicity concerns before any repurposing consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.